Changes of 8-Isoprostane, IL-6 and IL-10 in Exhaled Breath Condensate in COPD patients and Its Relationship with Airway Inflammation_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

LiXiaoli ,  HuangPing , DuXiufang

Department of Respiratory Medicine, The Affiliated Nanshan Hospital of Guangdong Medical College, Shenzhen, Guangdong, 518052, China;

Corresponding?author：

HuangPing, Email: sznshp@263.net

Keywords：

Chronic obstructive pulmonary disease; Airway inflammation; Exhaled breath condensate; Cytokines

DOI：

10.7507/1671-6205.2014110

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To monitor the airway inflammatory factors in exhaled breath condensate(EBC) of severe stable COPD patients during salmeterol/fluticasone (50/500μg, bid) treatment, and explore their clinical significance. Methods Twenty-four sever stable COPD patients and 18 healthy controls were included in the study. EBC was collected from COPD patients before treatment (day 0) and 14 days, 28 days, 90 days after treatment. Meanwhile lung function test and SGRQ score were measured.Concentrations of IL-6 and IL-10 were measured by liquid chip and 8-isoprostane by enzyme-linked immunosorbent assay. Results Levels of 8-isoprostane, IL-6 and IL-10 in EBC were significantly higher in the sever stable COPD patients before treatment compared with the healthy controls. 8-isoprostane was decreased significantly at day 14 compared with day 0[(11.59±4.12) pg/mL vs. (14.17±4.66) pg/mL, P < 0.05], and kept in low level till day 90 (P > 0.05). IL-6 was significantly decreased at day 28 compared with day 0[(1.46±0.19) pg/mL vs. (1.59±0.19) pg/mL, P < 0.05], but did not change significantly till day 90. IL-10 was in low level but showed increase at day 90 compared with day 28[(1.72±0.19) pg/mL vs. (1.62±0.12) pg/mL, P < 0.05]. FEV₁ and FEV₁/FVC were improved and SGRQ score was decreased after 90 days treatment (P < 0.05). FEV₁ was not correlated with 8-isoprostane, IL-6 or IL-10 level. Conclusions Dynamic observation of EBC 8-isoprostane level in severe COPD patients can help in evaluating drug efficacy. IL-10 may play a role in airway anti-inflammation.

Citation： LiXiaoli, HuangPing, DuXiufang. Changes of 8-Isoprostane, IL-6 and IL-10 in Exhaled Breath Condensate in COPD patients and Its Relationship with Airway Inflammation. Chinese Journal of Respiratory and Critical Care Medicine, 2014, 13(5): 445-448. doi: 10.7507/1671-6205.2014110 Copy

1.	Celli BR, Thomas NE, Anderson JA, et al.Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease:results from the TORCH study.Am J Respir Crit Care Med, 2008, 178:332-338.
2.	Jenkins CR, Jones PW, Calverley PM, et al.Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease:analysis from the randomised, placebo-controlled TORCH study.Respir Res, 2009, 10:59.
3.	陳金亮, 陳建榮, 陶一江, 等.慢性阻塞性肺疾病患者呼出氣冷凝液中白細胞三烯B4和腫瘤壞死因子-α的檢測及其臨床意義.中國危重病急救醫學, 2008, 20:357-360.
4.	Corhay JL, Henket M, Nguyen D, et al.Leukotriene B4 contributes to exhaled breath condensate and sputum neutrophil chemotaxis in COPD.Chest, 2009, 136:1047-1054.
5.	Borrill ZL, Roy K, Vessey RS, et al.Non-invasive biomarkers and pulmonary function in smokers.Int J Chron Obstrct Pulmom Dis, 2008, 3:171-183.
6.	Brindicci C, Ito K, Torre O, et al.Effects of aminoguanidine, an inhibitor of inducible nitric oxide synthase, on nitric oxide production and its metabolites in healthy control subjects, healthy smokers, and COPD patients.Chest, 2009, 135:353-367.
7.	孫健, 沈巨信, 周國忠, 等.COPD患者呼出氣冷凝液中8-異前列腺素及白細胞介素6水平的差異及臨床意義.中國呼吸與危重監護雜志, 2010, 9:137-140.
8.	Lehtim?ki L, Kankaanranta H, Saarelainen S, et al.Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD.Eur Respir J, 2010, 35:72-78.
9.	劉翱, 李少瑩, 楊偉康, 等.支氣管哮喘患者呼出氣冷凝液中8-異前列腺素水平的研究.中國呼吸與危重監護雜志, 2009, 8:337-340.
10.	Makris D, Paraskakis E, Korakas P, et al.Exhaled breath condensate 8-isoprostane, clinical parameters, radiological indices and airway inflammation in COPD.Respiration, 2008, 75:138-144.
11.	Carpagnano GE, Resta O, Foschino-Barbaro MP, et al.Exhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease:effect of carbocysteine lysine salt monohydrate (SCMC-Lys).Eur J Pharmacol, 2004, 505:169-175.
12.	Carpagnano GE, Kharitonov SA, Foschino-Barbaro MP, et al.Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation.Thorax, 2004, 59:1016-1019.
13.	Man SFP, Connett JE, Anthonisen NR, et al.C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease.Thorax, 2006, 61:849-853.
14.	Sin DD, Man SF, Marciniuk DD, et al.The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease.Am J Respir Crit Care Med, 2008, 177:1207-1214.
15.	Mukhopadhyay S, Hoidal JR, Mukherjee TK.Role of TNF-alpha in pulmonary pathophysiology.Respir Res, 2006, 7:125.
16.	朱崢, 周奇興, 鄒盈, 等.白介素8和白介素10在老年慢性阻塞性肺疾病誘導痰中的表達以及藥物治療對其的影響.國際呼吸雜志, 2012, 32:493-496.

1. Celli BR, Thomas NE, Anderson JA, et al.Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease:results from the TORCH study.Am J Respir Crit Care Med, 2008, 178:332-338.
2. Jenkins CR, Jones PW, Calverley PM, et al.Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease:analysis from the randomised, placebo-controlled TORCH study.Respir Res, 2009, 10:59.
3. 陳金亮, 陳建榮, 陶一江, 等.慢性阻塞性肺疾病患者呼出氣冷凝液中白細胞三烯B4和腫瘤壞死因子-α的檢測及其臨床意義.中國危重病急救醫學, 2008, 20:357-360.
4. Corhay JL, Henket M, Nguyen D, et al.Leukotriene B4 contributes to exhaled breath condensate and sputum neutrophil chemotaxis in COPD.Chest, 2009, 136:1047-1054.
5. Borrill ZL, Roy K, Vessey RS, et al.Non-invasive biomarkers and pulmonary function in smokers.Int J Chron Obstrct Pulmom Dis, 2008, 3:171-183.
6. Brindicci C, Ito K, Torre O, et al.Effects of aminoguanidine, an inhibitor of inducible nitric oxide synthase, on nitric oxide production and its metabolites in healthy control subjects, healthy smokers, and COPD patients.Chest, 2009, 135:353-367.
7. 孫健, 沈巨信, 周國忠, 等.COPD患者呼出氣冷凝液中8-異前列腺素及白細胞介素6水平的差異及臨床意義.中國呼吸與危重監護雜志, 2010, 9:137-140.
8. Lehtim?ki L, Kankaanranta H, Saarelainen S, et al.Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD.Eur Respir J, 2010, 35:72-78.
9. 劉翱, 李少瑩, 楊偉康, 等.支氣管哮喘患者呼出氣冷凝液中8-異前列腺素水平的研究.中國呼吸與危重監護雜志, 2009, 8:337-340.
10. Makris D, Paraskakis E, Korakas P, et al.Exhaled breath condensate 8-isoprostane, clinical parameters, radiological indices and airway inflammation in COPD.Respiration, 2008, 75:138-144.
11. Carpagnano GE, Resta O, Foschino-Barbaro MP, et al.Exhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease:effect of carbocysteine lysine salt monohydrate (SCMC-Lys).Eur J Pharmacol, 2004, 505:169-175.
12. Carpagnano GE, Kharitonov SA, Foschino-Barbaro MP, et al.Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation.Thorax, 2004, 59:1016-1019.
13. Man SFP, Connett JE, Anthonisen NR, et al.C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease.Thorax, 2006, 61:849-853.
14. Sin DD, Man SF, Marciniuk DD, et al.The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease.Am J Respir Crit Care Med, 2008, 177:1207-1214.
15. Mukhopadhyay S, Hoidal JR, Mukherjee TK.Role of TNF-alpha in pulmonary pathophysiology.Respir Res, 2006, 7:125.
16. 朱崢, 周奇興, 鄒盈, 等.白介素8和白介素10在老年慢性阻塞性肺疾病誘導痰中的表達以及藥物治療對其的影響.國際呼吸雜志, 2012, 32:493-496.

Chinese Journal of Respiratory and Critical Care Medicine

Changes of 8-Isoprostane, IL-6 and IL-10 in Exhaled Breath Condensate in COPD patients and Its Relationship with Airway Inflammation

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content